Saxenda Is Being Discontinued, and Rybelsus Tablets Are Being Replaced
Published: October 5, 2026 · 3 min read · By Grey Peptides News Desk · ✓ Sourced
FDA's drug shortage database now lists Saxenda, Novo Nordisk's daily liraglutide injection for weight management, as to be discontinued, with the product available until January 2027. It separately lists the original Rybelsus semaglutide tablets, at 3, 7 and 14 mg, as to be replaced by Ozempic tablets. Neither notice gives a reason beyond the discontinuation of manufacture.
What the notices say
FDA's drug shortage database carries a category for products their makers have said will be discontinued. On August 25, 2026, it posted a notice for Saxenda injection, 6 mg/mL: the product will be available until it is discontinued in January 2027. On June 4, 2026, it posted three notices for Rybelsus tablets, one each for the 3, 7 and 14 mg strengths, stating that these products will be replaced by Ozempic (semaglutide) tablets. We read all four through openFDA on October 5, 2026.
The notices are short. They say the manufacture of the drug is being discontinued and, for Rybelsus, what replaces it. They do not give a commercial or safety reason, and nothing in them suggests a safety problem; this post does not guess at one.
Saxenda: the end of daily liraglutide for weight
Saxenda is liraglutide at 3 mg a day, approved in 2014 for chronic weight management. It came years before the weekly drugs that now dominate the field: semaglutide as Wegovy and tirzepatide as Zepbound. Victoza, the lower-dose liraglutide for type 2 diabetes, is not named in the notice, and generic liraglutide was approved in 2024, so liraglutide itself is not leaving the market. People using Saxenda should talk to their prescriber before supply ends about what replaces it; our liraglutide entry covers the trials behind both doses.
Rybelsus: replaced, not removed
Rybelsus was the first oral semaglutide, approved for type 2 diabetes in 2019. Its label is now shared with a newer product, Ozempic tablets, which uses different strengths: 1.5 mg to start, then 4 or 9 mg, against Rybelsus's 3, 7 and 14 mg. The shared label says the two are not substitutable milligram for milligram, because the formulations deliver different amounts of semaglutide. A switch is therefore a prescriber's decision, not a pharmacy swap. Our guide to the semaglutide brands sets out how each product is taken.
What this does not change
Ozempic injection, Wegovy and the Wegovy pill are not among these notices, and neither is any tirzepatide product. Both molecules remain approved and available in other forms. Discontinuation is also not withdrawal of approval: Saxenda's and Rybelsus's approvals stay on FDA's records even after the products stop being made, which is why our FDA-approved peptides list separates approval from availability.
Related on Grey Peptides
Victoza, Saxenda and generic liraglutide: the trials, the doses and what is still sold. Semaglutide
Every semaglutide product, including the tablets, with label doses and trial results. Semaglutide brands explained
Ozempic, Wegovy, Rybelsus and the tablets: one molecule, different products. GLP-1 transition planner
How labels handle a switch between GLP-1 medicines, step by step.
US Food and Drug Administration - Drug Shortages database, discontinuation notices (via openFDA)
Saxenda notice posted August 25, 2026; Rybelsus notices posted June 4, 2026. Read October 5, 2026 through openFDA's drug/shortages endpoint.